Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Ltd Nirland Sells 939,009 Shares

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) major shareholder Ltd Nirland sold 939,009 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.10, for a total transaction of $93,900.90. Following the completion of the transaction, the insider now owns 6,092,000 shares in the company, valued at $609,200. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd Nirland also recently made the following trade(s):

• On Friday, October 4th, Ltd Nirland sold 1,368,991 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total value of $136,899.10.
• On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $33,317.70.
• On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.12, for a total transaction of $122,018.76.

Conduit Pharmaceuticals Price Performance

Shares of Conduit Pharmaceuticals stock opened at $0.10 on Tuesday. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $1.53. Conduit Pharmaceuticals Inc. has a 52-week low of $0.10 and a 52-week high of $7.83.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its earnings results on Monday, August 12th. The company reported ($0.07) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.